Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Head and Neck Neoplasms × S 1 (combination) × Clear all

Phase

Phase 2 3 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 10 Pancreatic Neoplasms 3 Colorectal Neoplasms 2 Rectal Neoplasms 1 Phase I: To Determine the Maximum Tolerated Dose (MTD) 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1 Adenocarcinoma 1

Interventions

pembrolizumab 22 Radiotherapy 17 Cisplatin 17 Cetuximab 11 Carboplatin 10 Nivolumab 8 Paclitaxel 7 durvalumab 6 Radiotherapy, Intensity-Modulated 5 Fluorouracil 5 Everolimus 4 Docetaxel 4 Cyclophosphamide 4 zalutumumab 3 spartalizumab 3 epacadostat 3 Ipilimumab 3 Immune Checkpoint Inhibitors 3 Gefitinib 3 Filgrastim 3 Celecoxib 3 Capecitabine 3 Amifostine 3 selpercatinib 2 fludarabine 2 cemiplimab 2 bintrafusp alfa protein, human 2 avelumab 2 Peripheral Blood Stem Cell Transplantation 2 Pemetrexed 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03654612 2018-10-18

Y-HR2017-025

China International Medical Foundation

Phase 1/2 Unknown

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡